Showing results (1-10 of 56) with videos related to
Sort By:
Pageof 6
NPJ Breast Cancer|August 20, 2022
Triple negative breast cancer: Pitfalls and progressPaola Zagami, Lisa Anne CareyCurrent Opinion in Oncology|July 14, 2020
Antibody-drug conjugates in breast cancer: the chemotherapy of the future?Eleonora Nicolò, Paola Zagami, Giuseppe CuriglianoCurrent Opinion in Oncology|September 9, 2024
Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectivesLiliana Ascione, Grazia Castellano, Giuseppe Curigliano, et al.Current Opinion in Oncology|August 25, 2023
HER2-positive breast cancer: cotargeting to overcome treatment resistancePaola Zagami, Luca Boscolo Bielo, Eleonora Nicolò, et al.Cancer Treatment and Research|January 4, 2024
New Concepts in Cardio-OncologyPaola Zagami, Eleonora Nicolò, Chiara Corti, et al.Journal of Clinical Medicine|September 10, 2020
Management of Cardiac Toxicity Induced by ChemotherapyDario Trapani, Paola Zagami, Eleonora Nicolò, et al.Expert Opinion on Investigational Drugs|November 22, 2022
The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022Beatrice Taurelli Salimbeni, Carla Corvaja, Carmine Valenza, et al.Journal of Personalized Medicine|December 29, 2022
PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-NegativeLiliana Ascione, Paola Zagami, Eleonora Nicolò, et al.Expert Review of Anticancer Therapy|August 27, 2019
What therapies are on the horizon for HER2 positive breast cancer?Giulia Viale, Stefania Morganti, Emanuela Ferraro, et al.Breast Cancer Research and Treatment|February 6, 2022
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?Stefania Morganti, Antonio Marra, Edoardo Crimini, et al.Pageof 6